52 results about "Prostate biopsy" patented technology

An MR-guided biopsy, for example, prostate biopsy, is performed by a mechanical tool for stabilizing the patient in prone position and for guiding the biopsy needle into defined targeted lesions in the prostate gland. The patient can lay prone in the MRI. The apparatus can guide an MR-visible, sterile needle sleeve, which can have a hollow tube filled with contrast media, through the anus onto the inner wall of the colon. Due to the visibility of the contrast media in the sleeve, the apparatus can be guided to the exact position. The sleeve can incorporate a tube within the contrast media filled sleeve to insert the biopsy needle and to push this needle forward into the prostate. The apparatus can utilize various mechanical mechanisms to stereotactically move the needle or needle sleeve in various directions.

The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and / or chemoprevention.

The invention relates to methods and kits for the diagnosis of prostate cancer (PCa) in a subject, for assessing or monitoring the response to a therapy in a subject having PCa or for monitoring the progression of prostate cancer PCa based on the detection of alteration in the expression levels of at least one gene selected from the group of PC A3, PSMA and PSGR. The invention relates as well to methods for assessing whether a subject has to be subjected to a prostate biopsy, said subject having a serum PSA range within 4-10 ng / mL.

The present invention provides a method of identifying a subject for whom a prostate biopsy is indicated, comprising: a) determining, from a nucleic acid sample obtained from the subject, a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; b) calculating a genetic risk score (GRS) for the subject based on the genotype determined in step (a); and c) analyzing the GRS of the subject in combination with a prostate specific antigen (PSA) level of the subject to identify a prostate cancer detection rate for the subject, whereby a prostate cancer detection rate of greater than or equal to a reference value identifies the subject as a subject for whom a prostate biopsy is indicated.

A method of analyzing a plurality of biopsy cores extracted from a plurality of respective biopsy locations in a prostate is disclosed. The method comprises: measuring a level of a chemical element in each of the biopsy cores, and generating a chemical element map of at least a portion of the prostate based on the levels and the respective biopsy locations. In some embodiments, the method determines at least one additional biopsy location for a future biopsy in the prostate.

The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and / or chemoprevention.

An anatomical sensing system-guided prostate procedure device that includes a housing having a proximal end and a distal end. The housing may be divided into a distal housing section, a mid housing section, and a proximal housing section, wherein the distal housing section is configured for insertion into the anus and retention in the rectum of a subject. The device further includes an instrument convergence point disposed between the proximal end and the distal end, the convergence point configured to allow an instrument pass though the instrument convergence point at a variable angle; and an instrument angle orienting system at the proximal end of the housing, the angle orienting system directing an orientation of the variable angle about the convergence point. Methods of the using an anatomical sensing system-guided prostate procedure device and system including the same.

A device for MR-guided endorectal prostate biopsy has a biopsy guidance device connected to an MR system that is secured to the patient support table, and is alignable via the MR system for alignment and guidance of the biopsy needle into a preselectable target area. The biopsy guidance device contains MR-imaging markers and is provided with a trajectory setting mechanism at which the previously selected and calculated trajectory can be set.

The invention presents tools to improve a 3-D image aided biopsy or treatment procedure for prostate gland by providing additional functionality and additional visual cues on an output image of the prostate, which may be generated substantially in real-time. The tools include i) the identification of various parts of prostate to classify as per regular classification in pathological reports, ii) Computing and displaying the insertion depth of needle with respect to a selected target point during the procedure, iii) Computing and displaying the distance from needle tip to prostate surface following a procedure and, iv) Calibration for misalignment of a 2-D imaging transducer when used under tracked motion for a procedure.

The invention discloses an adjusting device of an intra-cavity ultrasonic probe protection device and an application thereof. The adjusting device is used for prostate biopsy or radioactive particle implanting and comprises a tightening component, a fixing component, a guiding component and a connecting component. The tightening component is arranged on the fixing component, and a fixing portion is arranged on the fixing component and used for installing and fixing an ultrasonic probe protection sleeve. One end of the guiding component is movably connected with the fixing component, and the other end of the guiding component is fixedly connected with the connecting component. The connecting component is arranged below the fixing component and fixedly connected with the guiding component. Under the action of the tightening component, the fixing component can move along the guiding component; when the fixing component gets close to the connecting component, the ultrasonic probe protection device moves downwards and is close to the surface of an ultrasonic probe so that the ultrasonic probe protection device and the ultrasonic probe can be kept attached well; air in the space, between the inner wall of the upper portion of the ultrasonic probe protection sleeve and the external surface of the upper portion of the ultrasonic probe, for filling of medicinal ultrasonic coupling agents, is discharged, imaging quality is improved, and the usage quantity of the coupling agents is reduced.

The present disclosure relates to methods for the early detection of ERG over-expression, gene rearrangements, and diagnosis and / or prognosis of prostate cancer using a combined ERG IHC-FISH assay.

A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.